 Vital Capacity
"Vital Capacity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The volume of air that is exhaled by a maximal expiration following a maximal inspiration.
| Descriptor ID |
D014797
|
| MeSH Number(s) |
E01.370.386.700.485.750.900 G09.772.850.970
|
| Concept/Terms |
Vital Capacity- Vital Capacity
- Capacities, Vital
- Capacity, Vital
- Vital Capacities
Forced Vital Capacity- Forced Vital Capacity
- Capacities, Forced Vital
- Capacity, Forced Vital
- Forced Vital Capacities
- Vital Capacities, Forced
- Vital Capacity, Forced
|
Below are MeSH descriptors whose meaning is more general than "Vital Capacity".
Below are MeSH descriptors whose meaning is more specific than "Vital Capacity".
This graph shows the total number of publications written about "Vital Capacity" by people in this website by year, and whether "Vital Capacity" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 4 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 5 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 3 | 3 | | 2008 | 2 | 7 | 9 | | 2009 | 1 | 9 | 10 | | 2010 | 2 | 5 | 7 | | 2011 | 2 | 6 | 8 | | 2012 | 1 | 10 | 11 | | 2013 | 1 | 11 | 12 | | 2014 | 4 | 9 | 13 | | 2015 | 2 | 12 | 14 | | 2016 | 2 | 6 | 8 | | 2017 | 1 | 11 | 12 | | 2018 | 0 | 8 | 8 | | 2019 | 0 | 7 | 7 | | 2020 | 1 | 7 | 8 | | 2021 | 1 | 10 | 11 | | 2022 | 1 | 6 | 7 | | 2023 | 0 | 9 | 9 | | 2024 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Vital Capacity" by people in Profiles.
-
Rose JA, Tukpah AC, Cutting C, Wada N, Nishino M, Moll M, Kalra S, Choi B, Lynch DA, Raby BA, Rosas IO, San Jos? Est?par R, Washko GR, Silverman EK, Cho MH, Hatabu H, Putman RK, Hunninghake GM. Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene. Am J Respir Crit Care Med. 2024 Dec 15; 210(12):1453-1460.
-
Hayashi K, McDermott GC, Juge PA, Moll M, Cho MH, Wang X, Paudel ML, Doyle TJ, Kinney GL, Sansone-Poe D, Young K, Dellaripa PF, Wallace ZS, Regan EA, Hunninghake GM, Silverman EK, Ash SY, San Jose Estepar R, Washko GR, Sparks JA. Rheumatoid arthritis and changes on spirometry by smoking status in two prospective longitudinal cohorts. RMD Open. 2024 06 17; 10(2).
-
Zell-Baran LM, Krefft SD, Strand M, Rose CS. Longitudinal changes in lung function following post-9/11 military deployment in symptomatic veterans. Respir Med. 2024 06; 227:107638.
-
Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, Flaherty KR, Kazerooni EA, Maher TM, Richeldi L, Lasky JA, Swigris JJ, Busch R, Garrard L, Ahn DH, Li J, Puthawala K, Rodal G, Seymour S, Weir N, Danoff SK, Ettinger N, Goldin J, Glassberg MK, Kawano-Dourado L, Khalil N, Lancaster L, Lynch DA, Mageto Y, Noth I, Shore JE, Wijsenbeek M, Brown R, Grogan D, Ivey D, Golinska P, Karimi-Shah B, Martinez FJ. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Am J Respir Crit Care Med. 2024 03 15; 209(6):647-669.
-
Pugashetti JV, Lee JS. Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment. Semin Respir Crit Care Med. 2024 Jun; 45(3):329-341.
-
Ghazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Feb; 21(2):328-337.
-
Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, Baldwin M, Mueller H, Rohr KB, Flaherty KR. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024 Feb; 63(2).
-
Maher TM, Brown KK, Cunningham S, DeBoer EM, Deterding R, Fiorino EK, Griese M, Schwerk N, Warburton D, Young LR, Gahlemann M, Voss F, Stock C. Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach. Pediatr Pulmonol. 2024 Apr; 59(4):1038-1046.
-
Higbee DH, Lirio A, Hamilton F, Granell R, Wyss AB, London SJ, Bartz TM, Gharib SA, Cho MH, Wan E, Silverman E, Crapo JD, Lominchar JVT, Hansen T, Grarup N, Dantoft T, K?rhus L, Linneberg A, O'Connor GT, Dupuis J, Xu H, De Vries MM, Hu X, Rich SS, Barr RG, Manichaikul A, Wijnant SRA, Brusselle GG, Lahousse L, Li X, Hern?ndez Cordero AI, Obeidat M, Sin DD, Harris SE, Redmond P, Taylor AM, Cox SR, Williams AT, Shrine N, John C, Guyatt AL, Hall IP, Davey Smith G, Tobin MD, Dodd JW. Genome-wide association study of preserved ratio impaired spirometry (PRISm). Eur Respir J. 2024 01; 63(1).
-
England BR, Roul P, Yang Y, Hershberger D, Sayles H, Rojas J, Cannon GW, Sauer BC, Curtis JR, Baker JF, Mikuls TR. Extracting forced vital capacity from the electronic health record through natural language processing in rheumatoid arthritis-associated interstitial lung disease. Pharmacoepidemiol Drug Saf. 2024 01; 33(1):e5744.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|